Standout Papers

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre,... 2024 202648
  1. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial (2024)
    Yiming Mu, Freddy G. Eliaschewitz et al. The Lancet Diabetes & Endocrinology

Immediate Impact

59 standout
Sub-graph 1 of 23

Citing Papers

Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines
2025 Standout
GLP-1-based therapies for diabetes, obesity and beyond
2025 Standout
4 intermediate papers

Works of Ning Zu being referenced

Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial
2024 Standout
Efficacy and safety of once‐weekly semaglutide versus once‐daily sitagliptin as add‐on to metformin in patients with type 2 diabetes in SUSTAIN China : A 30‐week, double‐blind, phase 3a, randomized trial
2020

Author Peers

Author Last Decade Papers Cites
Ning Zu 128 194 110 15 418
Franck Péan 128 139 102 10 506
Hiroshi Tatsukawa 78 286 44 14 495
Ze Bo Hu 169 96 67 19 436
Monia Vezzoli 121 77 172 14 512
Johnny Nehmé 107 58 148 9 467
Atsunori Kuwabara 74 88 56 19 498
Sjoerd van Marle 60 88 84 19 459
A.R. Adamson 84 88 178 19 483
Reiko Nakashima 77 189 58 15 416
Yoshikata Morita 142 154 50 16 472

All Works

Loading papers...

Rankless by CCL
2026